- Home
- BIRD vs ACOG Comparison
BIRD vs ACOG Comparison
Compare BIRD & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- ACOG
- Stock Information
- Founded
- BIRD 2015
- ACOG 2000
- Country
- BIRD United States
- ACOG Canada
- Employees
- BIRD N/A
- ACOG N/A
- Industry
- BIRD Apparel
- ACOG
- Sector
- BIRD Consumer Discretionary
- ACOG
- Exchange
- BIRD Nasdaq
- ACOG Nasdaq
- Market Cap
- BIRD 89.7M
- ACOG 80.3M
- IPO Year
- BIRD 2021
- ACOG N/A
- Fundamental
- Price
- BIRD $6.36
- ACOG $9.50
- Analyst Decision
- BIRD Buy
- ACOG Strong Buy
- Analyst Count
- BIRD 2
- ACOG 1
- Target Price
- BIRD $11.00
- ACOG $20.00
- AVG Volume (30 Days)
- BIRD 76.8K
- ACOG 72.2K
- Earning Date
- BIRD 11-05-2025
- ACOG 08-14-2025
- Dividend Yield
- BIRD N/A
- ACOG N/A
- EPS Growth
- BIRD N/A
- ACOG N/A
- EPS
- BIRD N/A
- ACOG N/A
- Revenue
- BIRD $170,646,000.00
- ACOG $4,586,341.00
- Revenue This Year
- BIRD N/A
- ACOG N/A
- Revenue Next Year
- BIRD $4.20
- ACOG $149.89
- P/E Ratio
- BIRD N/A
- ACOG N/A
- Revenue Growth
- BIRD N/A
- ACOG N/A
- 52 Week Low
- BIRD $3.93
- ACOG $3.75
- 52 Week High
- BIRD $14.56
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- BIRD 37.74
- ACOG 59.31
- Support Level
- BIRD $6.28
- ACOG $8.01
- Resistance Level
- BIRD $6.81
- ACOG $8.34
- Average True Range (ATR)
- BIRD 0.41
- ACOG 0.49
- MACD
- BIRD 0.09
- ACOG 0.16
- Stochastic Oscillator
- BIRD 20.56
- ACOG 97.46
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.